Can someone explain how this drug works like I am not a scientist — anyone have experience?

Dr.NateNeph said:

PK/PD modeling for the pharmacology: understanding the pharmacokinetics helps optimize dosing.

Semaglutide structural biology relevant to the pharmacology: semaglutide is a 31-amino acid peptide with 94% homology to native GLP-1(7-36). Three key modifications enable its pharmacokinetic profile:

1. Aib8 substitution: DPP-4 resistance (prevents enzymatic degradation)
2. Arg34 substitution: improved chemical stability
3. C18 fatty diacid at Lys26: albumin binding → long half-life

These three modifications transform a peptide with a 2-minute half-life (native GLP-1) into one with a 168-hour half-life (semaglutide). A masterclass in peptide engineering.

DadBodDave said:

I went looking for why the dosing schedule is what it is and found that almost every practical question on this board has a pharmacokinetic answer…

Receptor pharmacology relevant to the pharmacology: semaglutide is a GLP-1R agonist with a C-18 fatty acid chain that enables albumin binding (>99%), creating a depot effect with a ~168-hour half-life enabling weekly dosing[1].

Tirzepatide is a dual GIP/GLP-1R agonist with higher GIP affinity (5:1 GIP:GLP-1 potency ratio). The GIP component may enhance beta-cell function and adipocyte lipid metabolism beyond what GLP-1 alone achieves.

For the pharmacology, the pharmacology explains the clinical differences between these agents.

Dr.CardioMD said:

Semaglutide structural biology relevant to the pharmacology: semaglutide is a 31-amino acid peptide with 94% homology to native GLP-1(7-36).

Pharmacist here. I want to add the drug interaction perspective on the pharmacology.

Key points from a pharmacokinetic standpoint:

• GLP-1 agonists delay gastric emptying, which can affect Tmax of co-administered oral medications
• Monitor patients on warfarin (INR), levothyroxine (TSH), and oral contraceptives during dose titration
• The albumin-binding mechanism of semaglutide (C-18 fatty acid linker) gives it the ~168-hour half-life that enables weekly dosing
• Steady state is reached at approximately 4-5 weeks after dose initiation or adjustment

Re: the pharmacology specifically — the pharmacology here is well-characterized and the clinical implications are straightforward.

One thing that is still open after RunnerRach’s answer:

Was that from a primary source or from a summary of one?

Closing the loop on my own question.

Update — tachyphylaxis to the gastric effect, persistence of the appetite effect. Two curves, and I had been watching the wrong one.